Abstract
Ribavirin, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxyamide (Virazole; Viratek, Inc., Covina, Calif.), has a broad spectrum of antiviral activity. However, the study of the absorption, metabolism, and excretion of this compound has been limited by the lack of an appropriate assay for ribavirin and its metabolites. Since ribavirin has definite potential for therapeutic use, we developed a radioimmunoassay to measure ribavirin levels in clinical specimens. To prepare an effective immunogen, ribavirin was monosuccinylated and coupled to ovalbumin. The competitive binding radioimmunoassay, in which tritium-labeled ribavirin and rabbit antiribavirin serum were used, was quantitative for ribavirin at concentrations of 1 pmol/100 microliter in urine or plasma samples. The rabbit antibody cross-reacted with the major metabolite of ribavirin, 1,2,4-triazole-3-carboxamide, at a low level (2 to 5%) which did not interfere with ribavirin binding until concentrations of 1,2,4-triazole-3-carboxamide 10- to 100-fold higher than ribavirin were present in mock samples, a condition not present in biological specimens. We used the ribavirin radioimmunoassay to determine the ribavirin concentration in mouse plasma after intraperitoneal administration, in the sera of adults from Sierra Leone after oral or intravenous administration for treatment of suspected Lassa fever, and in the sera of children in the United States after small-particle aerosol administration. Our experience with the radioimmunoassay indicates that it is sensitive, accurate, and reproducible. The assay will permit studies leading to a better understanding of the pharmacology and pharmacokinetics of this potentially useful antiviral drug.
Full text
PDF





Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baker D. C., Haskell T. H., Putt S. R. Prodrugs of 9-beta-D-arabinofuranosyladenine. 1. Synthesis and evaluation of some 5'-(O-acyl) derivatives. J Med Chem. 1978 Dec;21(12):1218–1221. doi: 10.1021/jm00210a009. [DOI] [PubMed] [Google Scholar]
- Berendt R. F., Walker J. S., Dominik J. W., Stephen E. L. Response of influenza virus-infected mice to selected doses of ribavirin administered intraperitoneally or by aerosol. Antimicrob Agents Chemother. 1977 Jun;11(6):1069–1070. doi: 10.1128/aac.11.6.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eriksson B., Helgstrand E., Johansson N. G., Larsson A., Misiorny A., Norén J. O., Philipson L., Stenberg K., Stening G., Stridh S. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother. 1977 Jun;11(6):946–951. doi: 10.1128/aac.11.6.946. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Goswami B. B., Borek E., Sharma O. K., Fujitaki J., Smith R. A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun. 1979 Aug 13;89(3):830–836. doi: 10.1016/0006-291x(79)91853-9. [DOI] [PubMed] [Google Scholar]
- Huffman J. H., Sidwell R. W., Khare G. P., Witkowski J. T., Allen L. B., Robins R. K. In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother. 1973 Feb;3(2):235–241. doi: 10.1128/aac.3.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Larson E. W., Stephen E. L., Walker J. S. Therapeutic effects of small-particle aerosols of ribavirin on parainfluenza (sendai) virus infections of mice. Antimicrob Agents Chemother. 1976 Oct;10(4):770–772. doi: 10.1128/aac.10.4.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Magnussen C. R., Douglas R. G., Jr, Betts R. F., Roth F. K., Meagher M. P. Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother. 1977 Oct;12(4):498–502. doi: 10.1128/aac.12.4.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Miller J. P., Kigwana L. J., Streeter D. G., Robins R. K., Simon L. N., Roboz J. The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann N Y Acad Sci. 1977 Mar 4;284:211–229. doi: 10.1111/j.1749-6632.1977.tb21953.x. [DOI] [PubMed] [Google Scholar]
- Quinn R. P., de Miranda P., Gerald L., Good S. S. A sensitive radioimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine]. Anal Biochem. 1979 Oct 1;98(2):319–328. doi: 10.1016/0003-2697(79)90148-9. [DOI] [PubMed] [Google Scholar]
- Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(4050):705–706. doi: 10.1126/science.177.4050.705. [DOI] [PubMed] [Google Scholar]
- Smith C. M., Fontenelle L. J., Muzik H., Paterson A. R., Unger H., Brox L. W., Henderson J. F. Inhibitors of inosinate dehydrogenase activity in Ehrlich ascites tumor cells in vitro. Biochem Pharmacol. 1974 Oct 1;23(19):2727–2735. doi: 10.1016/0006-2952(74)90043-4. [DOI] [PubMed] [Google Scholar]
- Stephen E. L., Jahrling P. B. Experimental Lassa fever virus infection successfully treated with ribavirin. Lancet. 1979 Feb 3;1(8110):268–269. doi: 10.1016/s0140-6736(79)90790-6. [DOI] [PubMed] [Google Scholar]
- Streeter D. G., Witkowski J. T., Khare G. P., Sidwell R. W., Bauer R. J., Robins R. K., Simon L. N. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A. 1973 Apr;70(4):1174–1178. doi: 10.1073/pnas.70.4.1174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Willis R. C., Carson D. A., Seegmiller J. E. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3042–3044. doi: 10.1073/pnas.75.7.3042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Witkowski J. T., Robins R. K., Sidwell R. W., Simon L. N. Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem. 1972 Nov;15(11):1150–1154. doi: 10.1021/jm00281a014. [DOI] [PubMed] [Google Scholar]